{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:03:42Z","timestamp":1792451022862,"version":"4.5.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T00:00:00Z","timestamp":1590019200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Fluoroquinolones are antibiotics prescribed in the outpatient setting, though they have serious side effects. This study evaluates the impact of stewardship interventions on total and inappropriate prescribing of fluoroquinolones in outpatient settings in a large county hospital and health system.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In an effort to decrease inappropriate outpatient fluoroquinolone usage, a multimodal antimicrobial stewardship initiative was implemented in November 2016. Education regarding the risks, benefits, and appropriate uses of fluoroquinolones was provided to providers in different outpatient settings, Food and Drug Administration warnings were added to all oral fluoroquinolone orders, an outpatient order set for cystitis treatment was created, and fluoroquinolone susceptibilities were suppressed when appropriate. Charts from October 2016, 2017, and 2018 were retrospectively reviewed if the patient encounter occurred in primary care clinics, emergency departments, or urgent care centers within Parkland Health &amp; Hospital System and a fluoroquinolone was prescribed. Inappropriate use was defined as a fluoroquinolone prescription for cystitis, bronchitis, or sinusitis in a patient without a history of Pseudomonas aeruginosa or multidrug-resistant organisms and without drug allergies that precluded use of other oral antibiotics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Total fluoroquinolone prescriptions per 1000 patient visits decreased significantly by 39% (P\u2005&amp;lt;\u2005.01), and inappropriate fluoroquinolone use decreased from 53% to 34% (P\u2005&amp;lt;\u2005.01). More than 90% of inappropriate fluoroquinolone prescriptions were given for cystitis, while bronchitis and sinusitis accounted for only 4.4% and 1.6% of inappropriate indications, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>A multimodal stewardship initiative appears to effectively reduce both total and inappropriate outpatient fluoroquinolone prescriptions.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofaa182","type":"journal-article","created":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T05:48:13Z","timestamp":1590040093000},"source":"Crossref","is-referenced-by-count":27,"title":["Decreased Outpatient Fluoroquinolone Prescribing Using a Multimodal Antimicrobial Stewardship Initiative"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7210-2127","authenticated-orcid":false,"given":"Kevin","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Parkland Health & Hospital System, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yorgo","family":"Zahlanie","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica K","family":"Ortwine","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Parkland Health & Hospital System, Dallas, Texas, USA"},{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman S","family":"Mang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Parkland Health & Hospital System, Dallas, Texas, USA"},{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Wei","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Parkland Health & Hospital System, Dallas, Texas, USA"},{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L Steven","family":"Brown","sequence":"first","affiliation":[{"name":"Department of Health System Research, Parkland Health & Hospital System, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie C","family":"Prokesch","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,5,21]]},"reference":[{"key":"2020061002243448800_CIT0001","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/cid\/ciy035","article-title":"Opportunities to improve fluoroquinolone prescribing in the United States for adult ambulatory care visits","volume":"67","author":"Kabbani","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2020061002243448800_CIT0002","author":"US Food and Drug Administration"},{"key":"2020061002243448800_CIT0003","author":"US Food and Drug Administration"},{"key":"2020061002243448800_CIT0004","article-title":"FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. News release","author":"US Food and Drug Administration"},{"key":"2020061002243448800_CIT0005","author":"US Food and Drug Administration"},{"key":"2020061002243448800_CIT0006","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1093\/infdis\/jiv279","article-title":"The rise of fluoroquinolone-resistant Escherichia coli in the community: scarier than we thought","volume":"212","author":"Spellberg","year":"2015","journal-title":"J Infect Dis"},{"key":"2020061002243448800_CIT0007","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.3201\/eid2209.160148","article-title":"Fluoroquinolone-resistant and extended-spectrum \u03b2-lactamase-producing Escherichia coli infections in patients with pyelonephritis, United States","volume":"22","author":"Talan","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"2020061002243448800_CIT0008","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1089\/mdr.2011.0139","article-title":"Fluoroquinolone resistance in uncomplicated acute pyelonephritis: epidemiology and clinical impact","volume":"18","author":"Shin","year":"2012","journal-title":"Microb Drug Resist"},{"key":"2020061002243448800_CIT0009","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jhin.2015.05.006","article-title":"Effects of fluoroquinolone restriction (from 2007 to 2012) on resistance in Enterobacteriaceae: interrupted time-series analysis","volume":"91","author":"Sarma","year":"2015","journal-title":"J Hosp Infect"},{"key":"2020061002243448800_CIT0010","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1186\/1756-0500-7-454","article-title":"Antibiotic consumption and its influence on the resistance in Enterobacteriaceae","volume":"7","author":"Sedl\u00e1kov\u00e1","year":"2014","journal-title":"BMC Res Notes"},{"key":"2020061002243448800_CIT0011","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s15010-012-0257-2","article-title":"Resistance surveillance studies: a multifaceted problem\u2014the fluoroquinolone example","volume":"40","author":"Dalhoff","year":"2012","journal-title":"Infection"},{"key":"2020061002243448800_CIT0012","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1128\/AAC.02897-15","article-title":"Antibiotic resistance among urinary isolates from female outpatients in the United States in 2003 and 2012","volume":"60","author":"Sanchez","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2020061002243448800_CIT0013","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1177\/8755122515599407","article-title":"Are fluoroquinolones appropriate for the treatment of extended-spectrum \u03b2-lactamase-producing gram-negative bacilli?","volume":"32","author":"Wiener","year":"2016","journal-title":"J Pharm Technol"},{"key":"2020061002243448800_CIT0014","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1128\/AAC.01131-09","article-title":"Treatment with fluoroquinolones or with beta-lactam-beta-lactamase inhibitor combinations is a risk factor for isolation of extended-spectrum-beta-lactamase-producing Klebsiella species in hospitalized patients","volume":"54","author":"Wener","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2020061002243448800_CIT0015","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jhin.2015.05.013","article-title":"Effects of fluoroquinolone restriction (from 2007 to 2012) on Clostridium difficile infections: interrupted time-series analysis","volume":"91","author":"Sarma","year":"2015","journal-title":"J Hosp Infect"},{"key":"2020061002243448800_CIT0016","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cix1085","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)","volume":"66","author":"McDonald","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2020061002243448800_CIT0017","doi-asserted-by":"crossref","first-page":"e026072","DOI":"10.1136\/bmjopen-2018-026072","article-title":"Impact of antimicrobial stewardship managed by clinical pharmacists on antibiotic use and drug resistance in a Chinese hospital, 2010-2016: a retrospective observational study","volume":"9","author":"Wang","year":"2019","journal-title":"BMJ Open"},{"key":"2020061002243448800_CIT0018","doi-asserted-by":"crossref","first-page":"XXX\u2013XX","DOI":"10.1093\/ofid\/ofz544","article-title":"Antibiotic prescribing in New York state Medicare Part B beneficiaries diagnosed with cystitis between 2016 and 2017","volume":"7","author":"Yu","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2020061002243448800_CIT0019","first-page":"116","article-title":"Urinary tract infections: leading initiatives in selecting empiric outpatient treatment (UTILISE)","volume":"67","author":"Landry","year":"2014","journal-title":"Can J Hosp Pharm"},{"key":"2020061002243448800_CIT0020","doi-asserted-by":"crossref","first-page":"e51147","DOI":"10.1371\/journal.pone.0051147","article-title":"A sustainable strategy to prevent misuse of antibiotics for acute respiratory infections","volume":"7","author":"Rattinger","year":"2012","journal-title":"PLoS One"},{"key":"2020061002243448800_CIT0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6506a1","article-title":"Core elements of outpatient antibiotic stewardship","volume":"65","author":"Sanchez","year":"2016","journal-title":"MMWR Recomm Rep"},{"key":"2020061002243448800_CIT0022","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1177\/1062860617716541","article-title":"Changing antibiotic prescribing in a primary care network: the role of readiness to change and group dynamics in success","volume":"33","author":"Elango","year":"2018","journal-title":"Am J Med Qual"},{"key":"2020061002243448800_CIT0023","first-page":"CD003539","article-title":"Interventions to improve antibiotic prescribing practices in ambulatory care","volume":"4","author":"Arnold","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"2020061002243448800_CIT0024","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1017\/ice.2014.41","article-title":"Antimicrobial stewardship in outpatient settings: a systematic review","volume":"36","author":"Drekonja","year":"2015","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2020061002243448800_CIT0025","volume-title":"Improving Antibiotic Prescribing for Uncomplicated Acute Respiratory Tract Infections. AHRQ Comparative Effectiveness Reviews","author":"McDonagh","year":"2016"},{"key":"2020061002243448800_CIT0026","doi-asserted-by":"crossref","first-page":"e801","DOI":"10.3399\/bjgp12X659268","article-title":"Effectiveness of physician-targeted interventions to improve antibiotic use for respiratory tract infections","volume":"62","author":"van der Velden","year":"2012","journal-title":"Br J Gen Pract"},{"key":"2020061002243448800_CIT0027","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.japh.2017.03.014","article-title":"Outpatient antibiotic stewardship: interventions and opportunities","volume":"57","author":"Dobson","year":"2017","journal-title":"J Am Pharm Assoc (2003)"},{"key":"2020061002243448800_CIT0028","volume-title":"Diffusion of Innovations","author":"Rogers","year":"1962"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaa182\/33243801\/ofaa182.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/6\/ofaa182\/33373705\/ofaa182.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/6\/ofaa182\/33373705\/ofaa182.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T06:25:56Z","timestamp":1591770356000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaa182\/5841404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,21]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaa182","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,6]]},"published":{"date-parts":[[2020,5,21]]},"article-number":"ofaa182"}}